skip to content

Contract Wins and Joint Ventures

Oxford BioMedica wins MHRA commercial supply licence

07 August 2017 08:20

Oxford BioMedica (OXB) has been granted a licence by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture and distribute lentiviral vector material for commercial supply.

This is in addition to the existing licence for Investigational Medicinal Products (IMPs) manufacture, which the group has held for over 10 years.

Oxford BioMedica recently signed an agreement with Novartis for the commercial and clinical supply of lentiviral vectors used to generate CTL019 and other undisclosed CAR-T products, for which Oxford BioMedica could potentially receive in excess of $100m from Novartis over the next three years.

In addition to the Novartis agreement, Oxford BioMedica has bioprocessing and process development partnerships with Immune Design and Orchard Therapeutics.

At 8:20am: (LON:OXB) Oxford BioMedica PLC share price was +0.05p at 9.37p

Story provided by StockMarketWire.com

Related Company: OXB

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.